Skip to main content
. Author manuscript; available in PMC: 2024 Mar 2.
Published in final edited form as: Cancer Chemother Pharmacol. 2023 Mar 2;91(3):281–290. doi: 10.1007/s00280-023-04511-0

Table 2.

Dose levels and dose-limiting toxicities

Dose level Adavosertib
(mg/day)
D1–5, 8–12
Oral
Belinostat (mg/
m2)
D1–5, 8–12
IV
#Treated/ #DLT
evaluable
DLT event Median # of
cycles (range)
1 200 600 3/3 2 (2–4)
2 200 800 3/3 4 (3–4)
3 225 800 9/3 1 (1–7)
4 225 1000 5/3 Gr4 CRS 2 (1–4)

CRS cytokine release syndrome, D day of the cycle, DLT dose-limiting toxicity, Gr grade of toxicity